David A Palma, Eitan Prisman, Eric Berthelet, Eric Tran, Sarah Hamilton, Jonn Wu, Antoine Eskander, Kevin Higgins, Irene Karam, Ian Poon, Zain Husain, Danny Enepekides, Michael Hier, Khalil Sultanem, Keith Richardson, Alex Mlynarek, Stephanie Johnson-Obaseki, Michael Odell, Andrew Bayley, Samuel Dowthwaite, James E Jackson, Marcin Dzienis, John O'Neil, Shamir Chandarana, Robyn Banerjee, Robert Hart, Jeffson Chung, Todd Tenenholtz, Suren Krishnan, Hien Le, John Yoo, Adrian Mendez, Eric Winquist, Sara Kuruvilla, Paul Stewart, Andrew Warner, Sylvia Mitchell, Jeff Chen, Christina Parker, Bret Wehrli, Keith Kwan, Julie Theurer, Jinka Sathya, J Alex Hammond, Nancy Read, Varagur Venkatesan, S Danielle MacNeil, Kevin Fung, Anthony C Nichols
IMPORTANCE: The optimal approach for treatment deescalation in human papillomavirus (HPV)-related oropharyngeal squamous cell carcinomas (OPSCCs) is unknown. OBJECTIVE: To assess a primary radiotherapy (RT) approach vs a primary transoral surgical (TOS) approach in treatment deescalation for HPV-related OPSCC. DESIGN, SETTING, AND PARTICIPANTS: This international, multicenter, open-label parallel-group phase 2 randomized clinical trial was conducted at 9 tertiary academic cancer centers in Canada and Australia and enrolled patients with T1-T2N0-2 p16-positive OPSCC between February 13, 2018, and November 17, 2020...
June 1, 2022: JAMA Oncology